Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
Dr. Miguel Gomez-Sanchez
Several forces contribute to the pathogenesis of pulmonary hypertension in patients with left-sided heart disease, with increased hydrostatic pressure leading to endothelial dysfunction and structural abnormalities in the pulmonary microcirculation as major contributors. Key events are breakage of the endothelial and alveolar basement membrane, with subsequent leakage of surfactant components into the systemic circulation.
How the balance of forces that causes permanent pulmonary vascular dysfunction is modulated, resulting in permanent pulmonary vascular disease in some patients, remains to be elucidated.
The cascade of events in heart failure that leads to pulmonary vascular disease ultimately affects right ventricular load and function, and leads to right ventricular failure and death.
Both systolic heart failure, and diastolic heart failure with preserved ventricular function may result in a variable degree of pulmonary hypertension. In diastolic heart failure, several pathogenetic mechanisms may play a role in an increasingly comorbid and elderly patient population.
In the intensive care setting, pulmonary hypertension associated with heart failure is a main target for a combination regimen of inotropic drugs (e.g. dobutamine, levosimendan) and vasodilators (e.g. NO and levosimendan).
There exist few controlled trials on classic pulmonary vasodilator treatments in chronic heart failure.
Current data suggest that pulmonary hypertension associated with chronic heart failure is a mechanical complication of disturbed left ventricular filling. Given the predominantly negative trial results regarding classic pulmonary vasodilator drugs in PH associated with heart failure, off-label use of these drugs for PH associated with left heart failure is currently not justified.
Pulmonary Hypertension in Left Heart Disease
This congress report accompanies a presentation given at the ESC Congress 2008. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved